NYSEAMERICAN:CRMDCorMedix Stock Price, Forecast & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CorMedix.

CorMedix is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for CorMedix.

CorMedix Inc. (NYSEAMERICAN:CRMD) released its quarterly earnings data on Monday, May, 11th. The biotechnology company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.02. The biotechnology company had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.15 million. View CorMedix's earnings history.

Shares of CorMedix reverse split on the morning of Tuesday, March 26th 2019. The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 25th 2019. An investor that had 100 shares of CorMedix stock prior to the reverse split would have 20 shares after the split.

2 brokers have issued twelve-month price objectives for CorMedix's stock. Their forecasts range from $12.00 to $14.00. On average, they expect CorMedix's stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 108.7% from the stock's current price. View analysts' price targets for CorMedix.

Media coverage about CRMD stock has trended very negative this week, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. CorMedix earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about CorMedix.

Some companies that are related to CorMedix include Biotest (BIO), Neptune Wellness Solutions (NEPT), Silence Therapeutics (SLN), TELIX Pharmaceutical (TLX), Starpharma (SPL), ProMetic Life Sciences (PLI), Pfenex (PFNX), IMV (IMV), Emblem (EMC), Medicenna Therapeutics (MDNA), Fennec Pharmaceuticals (FRX), Bioventix (BVXP), OncoCyte (OCX), Ergomed (ERGO) and Theratechnologies (TH). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other CorMedix investors own include ZIOPHARM Oncology (ZIOP), Rexahn Pharmaceuticals (REXN), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Amarin (AMRN), AcelRx Pharmaceuticals (ACRX), Progenics Pharmaceuticals (PGNX), Inovio Pharmaceuticals (INO), Kindred Biosciences (KIN) and Opko Health (OPK).

CorMedix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CRMD."

Shares of CRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CRMD stock can currently be purchased for approximately $6.23.

CorMedix has a market capitalization of $162.77 million. CorMedix employs 22 workers across the globe.

The official website for CorMedix is www.cormedix.com.

CorMedix's mailing address is 1430 US Highway 206 Ste 200, BEDMINSTER, NJ 07921-4602, United States. The biotechnology company can be reached via phone at +1-908-5179500.